Hints and tips:
Related Special Reports
Related Topics
...said Reddy. “This government treats everything as a public relations issue, not a public health issue.”...
...Corporate earnings: Companies set to report include Indian pharmaceuticals company Dr Reddy’s Laboratories, tech platform Grab and Chinese electronics manufacturer Xiaomi....
...Reddy’s added....
...These include Pratap Reddy, founder of Apollo Hospitals, whose family’s wealth is estimated at $2.8bn, up 169 per cent in a year, and Arvind Lal, the chair and owner of Dr Lal Pathlabs, whose family wealth...
...Until then, Dr Reddy's Laboratories, an Indian drugmaker, aims to import Sputnik doses into India once pricing issues are resolved....
...Dr Bhargava’s comments clash with health experts’ assessment of India’s handling of the pandemic....
...Last February, the group sold some of its branded generics business, which makes drugs that have come off patent, for Rs18.5bn to Dr Reddy’s Laboratories, one of India’s leading pharma groups....
...The company said a federal appeals court had denied its motion for a rehearing of its case against Dr Reddy’s Laboratories, after the court decided in November to vacate a preliminary injunction against...
...Shares closed down 47 per cent at an all-time low on Tuesday after Indivior said the US federal court of appeals had vacated a temporary injunction against Dr Reddy’s Laboratories, which makes a generic...
...If the mandate issues next Tuesday as scheduled, Indivior expects Dr Reddy’s and Alvogen Pine brook to both launch generic alternatives to its drug....
...Indivior shares dropped after the US chief justice threw out its challenge to a ruling that Dr Reddy’s Laboratories could start selling generic versions of the company’s blockbuster opiate addiction treatment...
...“The loss of a preliminary injunction on appeal by Dr Reddy’s was unexpected by the market and means that a generic can now be launched immediately,” said Citigroup....
...The company has been locked in a court battle with Dr Reddy’s Laboratories over the rollout in the US of the rival drugmaker’s generic version of Indivior’s top opioid addiction treatment Suboxone Film....
...It means Alvogen joins Dr Reddy’s, Sandoz and Mylan in being able to launch copycat versions as soon as the law allows....
...The US Food and Drug Administration approved two generic versions — from Mylan and Dr. Reddy’s Laboratories — in June 2018....
...Indivior is seeking to block the rival’s presence through the courts, and Dr Reddy’s has been temporarily banned from selling its Suboxone alternative in the US....
...“Indivior has managed to maintain its market position until mid-February although Dr Reddy’s, Mylan and Alvogen have now entered the market, along with an authorised generic from Sandoz....
...An appeal lodged by Dr Reddy Laboratories against a US court judgment blocking the sale of its generic version was unlikely to win, Jefferies argued....
...Reversing the decision that Dr Reddy infringed Indivior’s would require “a significant difference in opinion between the court rulings”, which appears unlikely, said Jefferies....
...Although Dr Reddy’s has been temporarily banned from selling its Suboxone alternative in the US, the US Court of Appeals in July granted the company’s motion to appeal the injunction....
...Shaun Thaxter, chief executive, said it was continuing to monitor developments in the US market to gauge the impact of Dr Reddy’s launch....
...The biggest threat comes from a rival product sold in the US by India’s Dr Reddy’s....
...Dr Reddy’s did not respond in time for comment....
...London-listed Indivior said the US Court of Appeals had granted rival Dr Reddy Laboratories’ motion to expedite its appeal against a temporary injunction, won by Indivior in July, that bans the sale or import...
International Edition